Hideki Tsutsumi
Overview
Explore the profile of Hideki Tsutsumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsutsumi H, Inoue R, Yasuda M, Takahashi R, Suzuki M, Urano K
J Toxicol Pathol
. 2022 Feb;
35(1):19-24.
PMID: 35221492
The rasH2 mouse was developed as a model for carcinogenicity studies in regulatory science. Its phenotype is stable during high-volume production and over successive generations. To produce rasH2 mice, three...
2.
Kusakawa S, Machida K, Yasuda S, Takada N, Kuroda T, Sawada R, et al.
Regen Ther
. 2019 Jun;
1:30-37.
PMID: 31245439
The contamination of human cell-processed therapeutic products (hCTPs) with tumorigenic cells is one of the major concerns in the manufacturing and quality control of hCTPs. However, no quantitative method for...
3.
Kawabe M, Urano K, Suguro M, Hara T, Kageyama Y, Mera Y, et al.
Vet Pathol
. 2019 Jun;
57(1):192-199.
PMID: 31221040
After initiation with 7,12-dimethylbenz[a]anthracene (DMBA), the promoting potential of 12--tetradecanoylphorbol-13-acetate (TPA) on skin tumor development can be detected by an ultra-short-term skin carcinogenicity bioassay using Tg-rasH2 mice. In the present...
4.
Mochizuki H, Murota N, Sato S, Nii K, Kouhei Y, Taniguchi M, et al.
J Toxicol Sci
. 2018 Nov;
43(11):685-695.
PMID: 30405001
We investigated the viability of a combined repeated dose toxicity study, including toxicokinetics (TK), in common marmosets according to the ICH-S4, ICH-S3A and ICH-S7A Guidelines using valsartan as test article...
5.
Yasuda S, Kusakawa S, Kuroda T, Miura T, Tano K, Takada N, et al.
PLoS One
. 2018 Oct;
13(10):e0205022.
PMID: 30286143
Human induced pluripotent stem cells (hiPSCs) represent promising raw materials of human cell-based therapeutic products (hCTPs). As undifferentiated hiPSCs exhibit intrinsic tumorigenicity properties that enable them to form teratomas, hCTPs...
6.
Ando K, Nishime C, Inoue R, Nishinaka E, Kawai K, Urano K, et al.
Behav Pharmacol
. 2017 Nov;
28(8):670-680.
PMID: 29099404
The differential effects of dopaminergic drugs with different pharmacological profiles were investigated with respect to spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of...
7.
Sato Y, Tsutsumi H, Sawada R, Suzuki T, Yasuda S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku
. 2013 Dec;
(131):16-9.
PMID: 24340665
Regenerative medicine is regarded as innovative therapy for severe diseases and damages caused by tissue loss and functional impairment. In Japan, regenerative medicine is one of the most important subjects...
8.
Takanashi S, Hara K, Aoki K, Usui Y, Shimizu M, Haniu H, et al.
Sci Rep
. 2012 Jul;
2:498.
PMID: 22787556
The application of carbon nanotubes (CNTs) as biomaterials is of wide interest, and studies examining their application in medicine have had considerable significance. Biological safety is the most important factor...
9.
Kadonosono T, Kuchimaru T, Yamada S, Takahashi Y, Murakami A, Tani T, et al.
PLoS One
. 2011 Nov;
6(11):e26640.
PMID: 22102864
An animal model for the early detection of common fatal diseases such as ischemic diseases and cancer is desirable for the development of new drugs and treatment strategies. Hypoxia-inducible factor...
10.
Machida K, Urano K, Yoshimura M, Tsutsumi H, Nomura T, Usui T
J Toxicol Sci
. 2008 Oct;
33(4):493-501.
PMID: 18827450
CByB6F1-Tg(HRAS)2Jic mice (brand name: rasH2 mouse) are produced by two breeding facilities, CLEA Japan, Inc. (Fuji, Shizuoka, Japan) and Taconic (Germantown, NY, USA), and supplied world wide. To confirm carcinogenic...